CrisprBits Raises $3M for CRISPR Infection Tests
28 Jul 2026
CrisprBits, a Bengaluru-based diagnostics startup applying CRISPR technology to detect antibiotic-resistant infections, has raised $3 million in a pre-Series A round at a $12 million valuation, the company announced in November 2025. The round brings the company's total disclosed funding to $3.25 million since its founding in 2020.
The Round
The pre-Series A was led by Spectrum Impact, the family office of Rajendra Gogri, Chairman and Managing Director of Aarti Industries. The Vijay Alreja Family Office, tied to VJ Technologies Group, returned as an investor, and the promoter family of HBL Engineering joined as a new backer. Notably, the round was funded entirely by family offices rather than institutional venture capital firms.
This follows a $250,000 pre-seed round raised in 2023 from the US-based VJ Group — the company's first outside capital since its 2020 founding.
What CrisprBits Has Built
CrisprBits was founded in 2020 by a team including CEO Vijay Chandru — who previously co-founded Strand Life Sciences and taught at the Indian Institute of Science — alongside Sunil Arora, Rajeev Kohli, Bharat Jobanputra and Aditya Sarda.
The company's core technology, its PathCrisp platform, was announced in February 2025 for early detection of antibiotic resistance in hospital-acquired infections. That announcement followed the January 2025 opening of a 7,300-square-foot research and prototype development facility in Bengaluru, where the platform is being developed.
CrisprBits also has an existing 2023 partnership with point-of-care testing company Molbio Diagnostics, which the report's opportunities section suggests could offer an established distribution channel for its diagnostic products.
Most recently, in December 2025, the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) signed a Letter of Intent with CrisprBits to jointly establish a Centre of Excellence for CRISPR Innovation and Translation. Specifics on what the centre will research or produce have not been disclosed.
Expansion Plans
As part of the November 2025 funding announcement, CrisprBits said it plans to expand its diagnostic products into Africa and Latin America within six months.
What's Not Yet Known
Several important details remain undisclosed. There is no public breakdown of how the $3 million will be allocated, no confirmation of regulatory approvals or clinical validation status for PathCrisp, and no published data on the platform's testing accuracy, turnaround time, or cost relative to existing diagnostics. The company has also not disclosed current revenue, customer base, or the scale of any commercial deployment. Information on competitors in the CRISPR diagnostics space is likewise absent from available facts.
Why Founders Should Care
For early-stage founders — particularly in deep tech and health diagnostics — CrisprBits' trajectory offers a few probabilistic signals worth weighing:
- The reliance on family offices rather than institutional VCs likely suggests an alternative capital path is viable for capital-intensive, long-development-cycle health-tech ventures, though it may also affect the pool and dynamics of future fundraising rounds.
- The relatively modest $12 million valuation at pre-Series A probably reflects the market's continued caution around unproven CRISPR diagnostic platforms, even after visible technical milestones like a dedicated facility and a named product platform.
- The sequencing here — facility buildout, then platform announcement, then funding — may indicate that demonstrating tangible R&D progress before fundraising can help justify valuation and attract capital, a pattern other deep-tech founders could consider emulating.
- The stated plan to expand into Africa and Latin America within six months of raising $3 million is an aggressive timeline relative to the company's overall funding history ($3.25 million to date). Founders eyeing similarly rapid international expansion should recognize that execution risk — regulatory, logistical, or otherwise — is real and, in this case, remains largely unaddressed publicly.
Bottom Line
CrisprBits has assembled a notable roster of family-office backers and academic partnerships to support its push into CRISPR-based diagnostics for drug-resistant infections. Its combination of a new Centre of Excellence, an existing Molbio Diagnostics partnership, and ambitious international expansion plans suggests real momentum. But with total funding still under $3.5 million and key details on regulatory status, unit economics, and competitive positioning unavailable, the company's next six to twelve months of execution will likely be the clearer test of whether its technical milestones can translate into commercial traction.